IDYA — IDEAYA Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1676725 ·
Last close
$27.40
Market Cap
$2.65B
52W High
$42.68
52W Low
$26.69
ADV30
1,011,309
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 10,242,000 — -137,632,000 -125,749,000 1,216,020,000 261,452,000 123,957,000
Jun 2026 8,857,000 — -122,291,000 -112,452,000 1,309,699,000 272,589,000 110,794,000
Mar 2026 6,560,000 — -108,544,000 -98,539,000 1,030,348,000 157,522,000 93,081,000
Dec 2025 10,876,000 — -94,570,000 -83,273,000 1,109,324,000 112,825,000 86,390,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-347,358,000
Investing CF
$-55,857,000
Financing CF
$366,216,000
CapEx
$-2,439,000
Dividends Paid
—
Buybacks
$-9,000
EPS Diluted TTM
$-4.49
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,073,279,000
Inventory
—
Receivables
$10,242,000
ST Investments
$577,089,000
EBIT TTM
$-463,037,000
Pretax Income TTM
$-420,013,000
Interest Exp TTM
—
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$36,536,000
EBITDA
$-460,324,992
Free Cash Flow
$-214,216,496
Enterprise Value
$2,211,900,416
Total Cash
$838,540,992
Total Debt
$29,703,000
Shares Out
96,694,575
Trailing EPS
$-4.50
Book Value
$11.30
ROE
-38.5%
ROA
-24.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 218,710,000 -159,313,000 -113,698,000 1,109,324,000 86,390,000 1,022,934,000 -71,098,000
Dec 2024 7,000,000 -326,975,000 -274,477,000 1,124,091,000 64,944,000 1,059,147,000 -247,584,000
Dec 2023 23,385,000 -134,429,000 -112,961,000 649,316,000 28,226,000 621,090,000 -115,224,000
Dec 2022 50,931,000 -62,502,000 -58,655,000 387,969,000 38,514,000 349,455,000 -87,175,000

TTM Snapshot

Revenues TTM
$234,127,000
NetIncome TTM
$-175,020,000
OpCashFlow TTM
—
Assets (Latest)
$1,309,699,000
Forward EPS
$-4.15

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $32.50 · spot: $26.49 · call volume: 280 · put volume: 108

Peers — same industry

TickerNameMarket CapLastDaily %
MBX MBX Biosciences, Inc. $2.64B $53.10 —
XNCR Xencor Inc $2.59B $34.50 —
HCM HUTCHMED (China) Ltd $2.50B $14.40 —
ZLAB Zai Lab Ltd $2.91B $23.53 —
RCUS Arcus Biosciences, Inc. $2.36B $16.39 —

News headlines (Yahoo Finance, 1h cache)

Is IDEAYA Biosciences (IDYA) Undervalued After Its FDA Backed IDE849 Trial Plan?
2026-11-18 01:12 · Yahoo
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TO
2026-11-16 21:05 · Yahoo
IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
2026-11-15 20:00 · Yahoo
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
2026-11-04 11:00 · Yahoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates
2026-11-03 11:25 · Yahoo
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
2026-11-03 11:00 · Yahoo
Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?
2026-10-31 05:13 · Yahoo
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-10-30 10:00 · Yahoo
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-10-27 13:00 · Yahoo
IDEAYA Biosciences (IDYA) Rethinks Its R And D Leadership As Undervaluation Questions Grow
2026-10-08 17:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.